News

Tim is the founder and CEO of Unchained Labs. He is a serial entrepreneur who has been building great life-sciences companies for over 25 years. Tim has under his belt three successful exits: Molecular Devices, ProteinSimple, and Unchained Labs (which together generated over $1.3 billion of shareholder value). He founded Unchained Labs to solve problems for researchers in biologics and gene therapy; in just over six years, he built it into an $80 million-plus business. To date, Tim has raised nearly $200 million in venture capital, helped raise over $1 billion in the public equity markets, and has participated in four successful exits as an independent board member. He is an enthusiastic supporter of other entrepreneurial teams and currently serves as an independent director of LabVoice.

Tim received a BBA from the University of Wisconsin and an MBA from Stanford University.

Mike Dybbs is a partner at Samsara BioCapital, where he invests across all stages of the life-science sector—from seed stage to public equities. He currently serves on the boards of Samsara portfolio companies that include Enara Bio, IONpath, Levo Therapeutics, Nkarta Therapeutics, and Sutro (STRO). Prior to Samsara, Mike was a partner at New Leaf Venture Partners. Mike has served on the boards of Versartis (VSAR), Dimension Therapeutics (DMTX), Advanced Cell Diagnostics (acquired by Bio-Techne), and Principia. Before joining New Leaf, Mike was a principal at the Boston Consulting Group, serving as a core member of its healthcare practice.

Mike received a AB in biochemical sciences from Harvard University and a PhD in molecular biology from the University of California, Berkeley, which also awarded him a Howard Hughes Medical Institute fellowship.

Wouter is a partner and member of the founding team at Illumina Ventures. He has more than 15 years of experience in the development and funding of life-science tools and genomics. Prior to joining Illumina Ventures, he served as the director of corporate development at Illumina Inc., where his main focus was venture investing and mergers-and-acquisitions. At Illumina, Wouter led investments that included Desktop Genetics (acquired in 2018 by Celixir) and Biota Technologies (currently an Illumina Ventures portfolio company).

Wouter graduated magna cum laude from the University of Ghent, Belgium, where he obtained BSc and MSc degrees in chemistry; he went on to earn a PhD in chemical engineering from the University of Newcastle in the United Kingdom and an MBA from the University of Cambridge, also in the U.K.

Bill is highly regarded for his expertise in research and clinical technology development. It is a reputation built on the development of commercially successful cytometric and genomic instrumentation and applications. Bill at present is the director of the Lab for Advanced Cytometry at the University of California, San Francisco, Department of Lab Medicine. He is also a venture partner at Genoa Ventures. Bill’s scientific work has appeared in over 100 peer-reviewed publications.

Bill received an MS degree from George Washington University and obtained a PhD from University Debrecen.

Adam is a world-renowned researcher in the area of high-throughput biological assays. Companies founded on the basis of his groundbreaking microfluidics discoveries include GnuBIO, Mission Bio, Scribe, and Fluent BioSciences. Currently a physicist with the University of California, San Francisco, Adam holds an appointment there as an associate professor of bioengineering and therapeutic sciences. More than 20 patents bear his name, as do 100 published studies. Additionally, Adam serves as an investigator for the Chan Zuckerberg Biohub and California Institute for Quantitative Biosciences.

Adam received a AB degree from Harvard University and a PhD from the University of Pennsylvania; he completed postdoctoral work at Harvard.